|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Naoki_Okamura
|
|
gptkbp:country
|
gptkb:Japan
|
|
gptkbp:focusArea
|
immunology
infectious diseases
oncology
transplantation
urology
|
|
gptkbp:formedByMergerOf
|
gptkb:Fujisawa_Pharmaceutical_Co.,_Ltd.
gptkb:Yamanouchi_Pharmaceutical_Co.,_Ltd.
|
|
gptkbp:founded
|
April 1, 2005
|
|
gptkbp:headquartersLocation
|
gptkb:Tokyo,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Astellas Pharma Inc.
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
JP3942400007
|
|
gptkbp:languageOfWork
|
English
Japanese
|
|
gptkbp:logo
|
Astellas Pharma logo.svg
|
|
gptkbp:marketCap
|
~US$30 billion (2023)
|
|
gptkbp:memberOf
|
gptkb:Japan_Pharmaceutical_Manufacturers_Association
|
|
gptkbp:netIncome
|
¥224.8 billion (FY2022)
|
|
gptkbp:notableAcquisition
|
gptkb:Audentes_Therapeutics
gptkb:Iveric_Bio
gptkb:Mitobridge
gptkb:OSI_Pharmaceuticals
gptkb:FibroGen_(Japan_rights)
gptkb:Ganymed_Pharmaceuticals
gptkb:Nanna_Therapeutics
gptkb:Ogeda
gptkb:Potenza_Therapeutics
gptkb:Universal_Cells
gptkb:Veloxis_Pharmaceuticals
gptkb:Xyphos_Biosciences
Quethera
|
|
gptkbp:numberOfEmployees
|
2022
~15,000
|
|
gptkbp:officialWebsite
|
https://www.astellas.com/
|
|
gptkbp:parentCompany
|
gptkb:Astellas_Group
|
|
gptkbp:products
|
gptkb:Prograf
gptkb:Vesicare
gptkb:Xtandi
gptkb:Myrbetriq
|
|
gptkbp:publiclyTraded
|
true
|
|
gptkbp:revenue
|
¥1,524.7 billion (FY2022)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:stockSymbol
|
4503
|
|
gptkbp:subsidiary
|
gptkb:Astellas_Pharma_Europe_Ltd.
gptkb:Astellas_US_LLC
|
|
gptkbp:tradedOn
|
gptkb:TYO:_4503
|
|
gptkbp:bfsParent
|
gptkb:Astellas_US
gptkb:Astellas_Pharma_Europe_Ltd.
gptkb:Astellas_US_LLC
|
|
gptkbp:bfsLayer
|
6
|